S Bank Fund Management Ltd Takes Position in Becton, Dickinson and Company $BDX

Key Points

• S Bank Fund Management Ltd acquired 29,657 shares of Becton, Dickinson and Company, valued at approximately $5.1 million, indicating growing institutional interest in the company.
• Several institutional investors, including Deroy & Devereaux and Mutual Advisors LLC, significantly increased their stakes, collectively owning 86.97% of the stock.
• Becton, Dickinson and Company recently announced a quarterly dividend of $1.04 per share, representing an annualized dividend yield of 2.2% and a payout ratio of 74.82%.

S Bank Fund Management Ltd purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 29,657 shares of the medical instruments supplier's stock, valued at approximately $5,108,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Deroy & Devereaux Private Investment Counsel Inc. boosted its stake in Becton, Dickinson and Company by 16.9% in the second quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 156,143 shares of the medical instruments supplier's stock valued at $26,896,000 after acquiring an additional 22,532 shares during the last quarter. Mutual Advisors LLC boosted its stake in Becton, Dickinson and Company by 32.9% in the second quarter. Mutual Advisors LLC now owns 3,959 shares of the medical instruments supplier's stock valued at $734,000 after acquiring an additional 980 shares during the last quarter. Twin Tree Management LP boosted its stake in Becton, Dickinson and Company by 1,227.5% in the second quarter. Twin Tree Management LP now owns 22,568 shares of the medical instruments supplier's stock valued at $3,887,000 after acquiring an additional 20,868 shares during the last quarter. Cypress Wealth Services LLC boosted its stake in Becton, Dickinson and Company by 18.9% in the second quarter. Cypress Wealth Services LLC now owns 3,592 shares of the medical instruments supplier's stock valued at $619,000 after acquiring an additional 570 shares during the last quarter. Finally, Courier Capital LLC boosted its stake in Becton, Dickinson and Company by 3.2% in the second quarter. Courier Capital LLC now owns 5,355 shares of the medical instruments supplier's stock valued at $922,000 after acquiring an additional 166 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BDX. Argus raised their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wells Fargo & Company lifted their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Piper Sandler reissued a "neutral" rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $205.40.

Becton, Dickinson and Company Trading Down 0.8%

Shares of NYSE:BDX opened at $186.76 on Thursday. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company's fifty day simple moving average is $190.74 and its 200 day simple moving average is $185.48. The firm has a market cap of $53.53 billion, a price-to-earnings ratio of 33.59, a PEG ratio of 1.47 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion for the quarter. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Insider Activity

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company's stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. The trade was a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,023 shares of company stock worth $562,036 over the last 90 days. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.